Literature DB >> 29248547

Dual Role of EZH2 in Cutaneous Anaplastic Large Cell Lymphoma: Promoting Tumor Cell Survival and Regulating Tumor Microenvironment.

Shengguo Yi1, Jingru Sun1, Lei Qiu1, Wenjing Fu2, Anqi Wang1, Xiaoqing Liu1, Yong Yang1, Marshall E Kadin3, Ping Tu1, Yang Wang4.   

Abstract

Primary cutaneous anaplastic T-cell lymphoma, characterized by the CD30+ anaplastic large T cells, comprises the second most common group of cutaneous T-cell lymphoma. Little is known about the mechanisms of disease progression. Here we report that enhancer of zeste homolog 2 (EZH2), the catalytic subunit of polycomb repressive complex 2 that mediates histone H3 lysine 27 trimethylation, is overexpressed in CD30+ anaplastic cells in primary cutaneous anaplastic T-cell lymphoma and large-cell transformed cutaneous T-cell lymphoma. Silencing EZH2 or inhibiting its histone methyltransferase activity conferred increased apoptosis and G1 cell-cycle arrest in primary cutaneous anaplastic T-cell lymphoma cells in vitro and a xenograft model in vivo. This was mediated by the de-repression of thioredoxin-interacting protein, a major redox control molecule, and consequent formation of reactive oxygen species. Silencing thioredoxin-interacting protein abrogated reactive oxygen species accumulation in EZH2 suppressed cells and rescued cell growth disadvantage. Moreover, EZH2 suppression de-repressed C-X-C motif chemokine ligand 10 and facilitated the recruitment of effector CD4+ and CD8+ T cells into the tumor microenvironment via a C-X-C motif chemokine ligand 10/receptor 3 interaction. These results demonstrate a dual role for polycomb repressive complex 2-mediated epigenetic silencing in tumor progression and antitumor immunity in primary cutaneous anaplastic T-cell lymphoma, and provide a rationale for the pharmacologic inhibition of EZH2 activity in large-cell transformed cutaneous T-cell lymphoma.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29248547     DOI: 10.1016/j.jid.2017.10.036

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  9 in total

1.  Induction of Transcriptional Inhibitor HES1 and the Related Repression of Tumor-Suppressor TXNIP Are Important Components of Cell-Transformation Program Imposed by Oncogenic Kinase NPM-ALK.

Authors:  Qian Zhang; Hong Y Wang; Anindita Nayak; Selene Nunez-Cruz; Artur Slupianek; Xiaobin Liu; Johnvesly Basappa; Jing-Song Fan; Seble Chekol; Reza Nejati; Agata M Bogusz; Suzanne D Turner; Kunchithapadam Swaminathan; Mariusz A Wasik
Journal:  Am J Pathol       Date:  2022-05-28       Impact factor: 5.770

Review 2.  CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies.

Authors:  Lucia Prieto-Torres; Socorro M Rodriguez-Pinilla; Arantza Onaindia; Mariano Ara; Luis Requena; Miguel Á Piris
Journal:  Haematologica       Date:  2019-01-10       Impact factor: 9.941

Review 3.  Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials.

Authors:  Pan Lai; Yang Wang
Journal:  Cancer Biol Med       Date:  2021-02-15       Impact factor: 4.248

Review 4.  Epigenetics of Cutaneous T-Cell Lymphomas.

Authors:  Natsumi Hara; Yu Sawada
Journal:  Int J Mol Sci       Date:  2022-03-24       Impact factor: 5.923

5.  Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma.

Authors:  Armando N Bastidas Torres; Rutger C Melchers; Liana Van Grieken; Jacoba J Out-Luiting; Hailiang Mei; Cedrick Agaser; Thomas B Kuipers; Koen D Quint; Rein Willemze; Maarten H Vermeer; Cornelis P Tensen
Journal:  Haematologica       Date:  2022-07-01       Impact factor: 11.047

Review 6.  Polycomb Directed Cell Fate Decisions in Development and Cancer.

Authors:  Beatriz German; Leigh Ellis
Journal:  Epigenomes       Date:  2022-09-06

Review 7.  MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas.

Authors:  Maria Gluud; Andreas Willerslev-Olsen; Lise Mette Rahbek Gjerdrum; Lise M Lindahl; Terkild B Buus; Mads Hald Andersen; Charlotte Menne Bonefeld; Thorbjorn Krejsgaard; Ivan V Litvinov; Lars Iversen; Jürgen C Becker; Jenny L Persson; Sergei B Koralov; Thomas Litman; Carsten Geisler; Anders Woetmann; Niels Odum
Journal:  Cancers (Basel)       Date:  2020-05-13       Impact factor: 6.639

Review 8.  EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.

Authors:  Boheng Li; Wee-Joo Chng
Journal:  J Hematol Oncol       Date:  2019-11-21       Impact factor: 17.388

9.  Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas.

Authors:  Franziska Lea Schümann; Elisabeth Groß; Marcus Bauer; Christian Rohde; Sarah Sandmann; Denis Terziev; Lutz P Müller; Guido Posern; Andreas Wienke; Falko Fend; Martin-Leo Hansmann; Wolfram Klapper; Andreas Rosenwald; Harald Stein; Martin Dugas; Carsten Müller-Tidow; Claudia Wickenhauser; Mascha Binder; Thomas Weber
Journal:  Biomedicines       Date:  2021-12-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.